Vials of the Pfizer-BioNTech Covid-19 vaccine.
Photographer: Cole Burston / Bloomberg
Photographer: Cole Burston / Bloomberg
Partner of Pfizer Inc. BioNTech SE is pursuing all options to make more doses of Covid-19 vaccine than the 1.3 billion the companies have promised to produce next year, according to the German company’s chief executive.
The companies may know by at least January or February and how many additional doses will be delivered, Ugur Sahin said Monday. “I’m confident we can increase our network capacity, but we don’t have numbers yet,” he said in an interview.
Efficiency products of more than 90% and worldwide licenses have started a race between countries for more supply of the valuable sights, with the U.S. trying to make a choice for one hundred million. It has already been discussed for most of the doses expected next year – enough to vaccinate 650 million people.
More than 2 million people in six countries have already had their first glimpse of the standard two-dose regimen, according to data collected by Bloomberg.
Read More: Pfizer-BioNTech Shot Likely Beats New Covid Strain, EMA says
BioNTech is looking for more of the raw materials it needs for its mRNA vaccine, more clean rooms and more collaboration partners, Sahin said. The company also needs extra space to design the photos, ship them and prepare them for delivery, he said. Pfizer manufactures vaccines at three sites in the US and one in Europe, and BioNTech has two manufacturing sites in Germany.
The EU vaccination agreement and an inclusion campaign set to begin there on December 27 promise further stocktaking. The participants have already begun sending photos to the UK, where Health Secretary Matt Hancock on Monday tweeted that around 500,000 people had received the first dose.
New Strain Tests
The bullet may be effective against the new SARS-CoV-2 strain that has surfaced in the UK, Sahin said. Lab tests on vaccine performance have already been performed against 20 mutant versions of SARS-CoV-2; the same tests will now be carried out against the new version in the UK, and it should take about two weeks, he said.
Most vaccines target the spike protein, which allows the virus to enter cells.
“This virus has many variants, but as far as we know, 99% of spike proteins are not suppressed,” he said. “We will do the test and get the result. That’s always the best response, but I would emphasize just being calm. ”
– Supported by Riley Griffin